Accro Bioscience

Suzhou, China · Founded 2017 · Privately Held (backing)

Developer of small molecule innovative drugs designed for inflammatory, autoimmune diseases and cancer. Accro Bioscience is based in Suzhou, China and was founded in 2017. Its last reported valuation was $161 million in Jan 2022. It has raised $62 million.

Last reported valuation
$161.0M
Oct 2026
Priced at
—
Total raised
$62.0M
Last round
—

Who backs Accro Bioscience?

10 investors
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Accro Bioscience investors

10 investors are on record for Accro Bioscience, including Suzhou Oriza Holdings Corporation, Shenzhen Capital Group, Hefei Innovation Technology Venture Capital and 5Y Capital. By type, the record holds 4 venture capital firms and 1 asset manager.

Free account
More of Accro Bioscience with a free account
  • ·Watch Accro Bioscience: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 10 firms already write checks for companies like Accro Bioscience. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View